← Back to Search

N/A

Treatment for Ductal Carcinoma (ELISA Trial)

N/A
Recruiting
Led By Tim Whelan, M.D.
Research Sponsored by Ontario Clinical Oncology Group (OCOG)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 year
Awards & highlights

Summary

To evaluate whether the combination of clinicopathological factors and the use of the Oncotype DX DCIS score can avoid radiation in women with low risk DCIS who have had breast conserving surgery (BCS)

Eligible Conditions
  • Ductal Carcinoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Ipsilateral local recurrence (LR)
Secondary outcome measures
Breast cancer recurrence-free interval (RFI)
Disease-free survival (DFS)
Distant disease-free survival (DDFS)
+2 more

Find a Location

Who is running the clinical trial?

Ontario Clinical Oncology Group (OCOG)Lead Sponsor
63 Previous Clinical Trials
41,399 Total Patients Enrolled
Tim Whelan, M.D.Principal InvestigatorJuravinski Cancer Centre
1 Previous Clinical Trials
281 Total Patients Enrolled
Eileen Rakovitch, M.DPrincipal InvestigatorSunnybrook Research Institute, Sunnybrook Health Science
~351 spots leftby Mar 2035
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top